Jennifer Lois McKimm-Breschkin

List of Publications by Year
in descending order

64 papers	5,337 citations	136950 32 h-index	118850 62 g-index
66 all docs	66 docs citations	66 times ranked	5896 citing authors

#	Article	IF	Citations
1	ER Stress Triggers Apoptosis by Activating BH3-Only Protein Bim. Cell, 2007, 129, 1337-1349.	28.9	1,235
2	The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins: Structure, Function and Bioinformatics, 1992, 14, 327-332.	2.6	399
3	Detection of Influenza Viruses Resistant to Neuraminidase Inhibitors in Global Surveillance during the First 3 Years of Their Use. Antimicrobial Agents and Chemotherapy, 2006, 50, 2395-2402.	3.2	333
4	Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza and Other Respiratory Viruses, 2013, 7, 25-36.	3.4	291
5	Influenza Virus Neuraminidase Structure and Functions. Frontiers in Microbiology, 2019, 10, 39.	3.5	280
6	Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase. Structure, 1998, 6, 735-746.	3.3	210
7	Structure of the Haemagglutinin-neuraminidase from Human Parainfluenza Virus Type III. Journal of Molecular Biology, 2004, 335, 1343-1357.	4.2	200
8	Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity. Science, 2013, 340, 71-75.	12.6	175
9	Mutations in a Conserved Residue in the Influenza Virus Neuraminidase Active Site Decreases Sensitivity to Neu5Ac2en-Derived Inhibitors. Journal of Virology, 1998, 72, 2456-2462.	3.4	175
10	The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody. Structure, 1994, 2, 733-746.	3.3	157
11	Generation and Characterization of an Influenza Virus Neuraminidase Variant with Decreased Sensitivity to the Neuraminidase-Specific Inhibitor 4-Guanidino-Neu5Ac2en. Virology, 1995, 214, 475-484.	2.4	155
12	Reduced Sensitivity of Influenza A (H5N1) to Oseltamivir. Emerging Infectious Diseases, 2007, 13, 1354-1357.	4.3	108
13	The Interaction of Neuraminidase and Hemagglutinin Mutations in Influenza Virus in Resistance to 4-Guanidino-Neu5Ac2en. Virology, 1998, 246, 95-103.	2.4	101
14	A simplified plaque assay for respiratory syncytial virusâ€"direct visualization of plaques without immunostaining. Journal of Virological Methods, 2004, 120, 113-117.	2.1	96
15	Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro. Journal of Antimicrobial Chemotherapy, 2006, 58, 723-732.	3.0	94
16	Dimeric Zanamivir Conjugates with Various Linking Groups Are Potent, Long-Lasting Inhibitors of Influenza Neuraminidase Including H5N1 Avian Influenza. Journal of Medicinal Chemistry, 2005, 48, 2964-2971.	6.4	82
17	Structural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B Viruses. Journal of Medicinal Chemistry, 2010, 53, 6421-6431.	6.4	75
18	Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996â€"2007. Antiviral Therapy, 2009, 14, 751-762.	1.0	71

#	Article	IF	Citations
19	The use of tetramethylbenzidine for solid phase immunoassays. Journal of Immunological Methods, 1990, 135, 277-280.	1.4	67
20	Neuraminidase Inhibitor-Resistant and -Sensitive Influenza B Viruses Isolated from an Untreated Human Patient. Antimicrobial Agents and Chemotherapy, 2006, 50, 1872-1874.	3.2	66
21	Reduced Sensitivity of Influenza A (H5N1) to Oseltamivir. Emerging Infectious Diseases, 2007, 13, 1354-1357.	4.3	65
22	Management of Influenza Virus Infections with Neuraminidase Inhibitors. Treatments in Respiratory Medicine, 2005, 4, 107-116.	1.4	62
23	Complexity in Influenza Virus Targeted Drug Design: Interaction with Human Sialidases. Journal of Medicinal Chemistry, 2010, 53, 2998-3002.	6.4	62
24	Inhibition of Parainfluenza Virus Type 3 and Newcastle Disease Virus Hemagglutinin-Neuraminidase Receptor Binding: Effect of Receptor Avidity and Steric Hindrance at the Inhibitor Binding Sites. Journal of Virology, 2004, 78, 13911-13919.	3.4	51
25	The neuraminidases of MDCK grown human influenza A(H3N2) viruses isolated since 1994 can demonstrate receptor binding. Virology Journal, 2015, 12, 67.	3.4	42
26	A Generic System for the Expression and Purification of Soluble and Stable Influenza Neuraminidase. PLoS ONE, 2011, 6, e16284.	2.5	41
27	Reduced susceptibility to all neuraminidase inhibitors of influenza H1N1 viruses with haemagglutinin mutations and mutations in non-conserved residues of the neuraminidase. Journal of Antimicrobial Chemotherapy, 2013, 68, 2210-2221.	3.0	40
28	Neuraminidase inhibitors for the treatment and prevention of influenza. Expert Opinion on Pharmacotherapy, 2002, 3, 103-112.	1.8	37
29	Structure of a calcium-deficient form of influenza virus neuraminidase: implications for substrate binding. Acta Crystallographica Section D: Biological Crystallography, 2006, 62, 947-952.	2.5	36
30	Real Time Enzyme Inhibition Assays Provide Insights into Differences in Binding of Neuraminidase Inhibitors to Wild Type and Mutant Influenza Viruses. PLoS ONE, 2011, 6, e23627.	2.5	35
31	In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir. Journal of Antimicrobial Chemotherapy, 2012, 67, 1874-1883.	3.0	27
32	Identification of a human influenza type B strain with reduced sensitivity to neuraminidase inhibitor drugs. Virus Research, 2004, 103, 205-211.	2.2	26
33	Pertussigen enhances antigen-driven interferon-Î³ production by sensitized lymphoid cells. Cellular Immunology, 1986, 97, 238-247.	3.0	25
34	Influenza polymerase inhibitor resistance: Assessment of the current state of the art - A report of the isirv Antiviral group. Antiviral Research, 2021, 194, 105158.	4.1	24
35	Antiviral Activity and Structural Characteristics of the Nonglycosylated Central Subdomain of Human Respiratory Syncytial Virus Attachment (G) Glycoprotein. Journal of Biological Chemistry, 2001, 276, 38988-38994.	3.4	22
36	Tethered Neuraminidase Inhibitors That Bind an Influenza Virus: A First Step Towards a Diagnostic Method for Influenza. Angewandte Chemie - International Edition, 2003, 42, 3118-3121.	13.8	22

#	Article	IF	Citations
37	Taking down the FLAG! How Insect Cell Expression Challenges an Established Tag-System. PLoS ONE, 2012, 7, e37779.	2.5	21
38	I222 Neuraminidase Mutations Further Reduce Oseltamivir Susceptibility of Indonesian Clade 2.1 Highly Pathogenic Avian Influenza A(H5N1) Viruses. PLoS ONE, 2013, 8, e66105.	2.5	21
39	COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment â€“ Meeting report from an isirv-WHO virtual conference. Antiviral Research, 2022, 197, 105227.	4.1	19
40	News About Influenza B Drug Resistance That Cannot Be Ignored. JAMA - Journal of the American Medical Association, 2007, 297, 1492-3.	7.4	16
41	Substrate, Inhibitor, or Antibody Stabilizes the Glu 119 Gly Mutant Influenza Virus Neuraminidase. Virology, 1998, 247, 14-21.	2.4	15
42	Catalytic mechanism and novel receptor binding sites of human parainfluenza virus type 3 hemagglutinin-neuraminidase (hPIV3 HN). Antiviral Research, 2015, 123, 216-223.	4.1	15
43	Neuraminidase mutations conferring resistance to laninamivir lead to faster drug binding and dissociation. Antiviral Research, 2015, 114, 62-66.	4.1	15
44	Expression of influenza neuraminidase in baculovirus-infected cells. Virus Research, 1992, 26, 127-139.	2.2	14
45	Preparation of T cell growth factor free from interferon and factors stimulating hemopoietic cells and mast cells. Journal of Immunological Methods, 1982, 51, 311-322.	1.4	13
46	P Cell Stimulating Factor Release: A Useful Assay of T Cell Activation in vitro. International Archives of Allergy and Immunology, 1986, 79, 169-177.	2.1	10
47	Identification of Indonesian clade 2.1 highly pathogenic influenza A(H5N1) viruses with N294S and S246N neuraminidase substitutions which further reduce oseltamivir susceptibility. Antiviral Research, 2018, 153, 95-100.	4.1	10
48	Plaque Formation Assay for Human Parainfluenza Virus Type 1. Biological and Pharmaceutical Bulletin, 2011, 34, 996-1000.	1.4	9
49	Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro-N-acetylneuraminic Acid Derivatives. Journal of Medicinal Chemistry, 2018, 61, 1921-1933.	6.4	9
50	Changes in the NS gene of neurovirulent strains of influenza affect splicing. Virus Genes, 1995, 10, 91-94.	1.6	7
51	Mixed influenza A and B infections complicate the detection of influenza viruses with altered sensitivities to neuraminidase inhibitors. Antiviral Research, 2011, 91, 20-22.	4.1	7
52	Structure of an Influenza A virus N9 neuraminidase with a tetrabrachion-domain stalk. Acta Crystallographica Section F, Structural Biology Communications, 2019, 75, 89-97.	0.8	7
53	Mechanisms of resistance of influenza virus to neuraminidase inhibitors. International Congress Series, 2001, 1219, 855-861.	0.2	6
54	Passaging of an influenza A(H1N1)pdm09 virus in a difluoro sialic acid inhibitor selects for a novel, but unfit I106M neuraminidase mutant. Antiviral Research, 2019, 169, 104542.	4.1	5

#	Article	IF	Citations
55	Complete nucleotide sequence of the non-structural gene of the human influenza virus strain A/WS/33. Nucleic Acids Research, 1993, 21, 2257-2257.	14.5	4
56	Biochemical Methods for the Characterization of Influenza Viruses with Reduced Sensitivity to 4-Guanidino-Neu5Ac2en. , 2000, 24, 367-374.		4
57	Solid phase assay for comparing reactivation rates of neuraminidases of influenza wild type and resistant mutants after inhibitor removal. Antiviral Research, 2014, 108, 30-35.	4.1	4
58	Virological Methods for the Generation and Characterization of Influenza Viruses with Reduced Sensitivity to 4-Guanidino-Neu5Ac2en. , 2000, 24, 375-382.		3
59	Interferon Induction by Measles Virus. Intervirology, 1981, 16, 250-259.	2.8	2
60	Rapid treatment of whole cells and RNA viruses for analysis of RNA by slot blot hybridization. Virus Research, 1992, 22, 199-206.	2.2	2
61	Use of oligonucleotide probes for selecting potential high-yielding influenza reassortants. Journal of Virological Methods, 1997, 68, 139-145.	2.1	2
62	Substitutions at H134 and in the 430-loop region in influenza B neuraminidases can confer reduced susceptibility to multiple neuraminidase inhibitors. Antiviral Research, 2020, 182, 104895.	4.1	1
63	Stereoselective synthesis and sialidase inhibition properties of KDO-based glycosyloxathiins. Arkivoc, 2014, 2014, 65-79.	0.5	1
64	A clinical trial lacking a control group. International Journal of Infectious Diseases, 2019, 89, 189.	3.3	0